Discussion: Treatment of Neurocognitive Disorders:Mild Cognitive Impairment

To prepare for this Discussion:

  • By Day 5 of Week 7, your Instructor will have assigned you a neurocognitive disorder,( Mild Cognitive Impairment)which will be the focus for your initial post for this Discussion.
  • Review the Learning Resources.

Post:

  • Explain the diagnostic criteria for your assigned neurocognitive disorder.
  • Explain the evidenced-based psychotherapy and psychopharmacologic treatment for your assigned neurocognitive disorder.
  • Identify the risks of different types of therapy and explain how the benefits of the therapy that might be achieved might outweigh the risks.
  • Support your rationale with references to the Learning Resources or other academic resource.

Required Readings

Sadock, B. J., Sadock, V. A., & Ruiz, P. (2014). Kaplan & Sadock’s synopsis of psychiatry: Behavioral sciences/clinical psychiatry (11th ed.). Philadelphia, PA: Wolters Kluwer.

  • Chapter 21, “Neurocognitive Disorders” (pp. 694–741)

Gabbard, G. O. (2014). Gabbard’s treatment of psychiatric disorders (5th ed.). Washington, DC: American Psychiatric Publications.

  • Chapter 63, “Delirium”
  • Chapter 64, “Neurocognitive Disorder Due to Alzheimer’s Disease”
  • Chapter 65, “Frontotemporal Neurocognitive Disorder”
  • Chapter 66, “Vascular Neurocognitive Disorder”
  • Chapter 67, “Neurocognitive Disorder Due to Parkinson’s Disease”

American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders (5th ed.). Washington, DC: Author.

  • “Neurocognitive Disorders”

Stahl, S. M. (2014). Prescriber’s Guide: Stahl’s Essential Psychopharmacology (5th ed.). New York, NY: Cambridge University Press.

 

Note: All Stahl resources can be accessed through the Walden Library using the link below. This link will take you to a login page for the Walden Library. Once you log in to the library, the Stahl website will appear. http://ezp.waldenulibrary.org/login?url=http://stahlonline.cambridge.org/

 

To access information on specific medications, click on The Prescriber’s Guide, 5th Ed. tab on the Stahl Online website and select the appropriate medication.

 

 

Alzheimer disease Delirium Dementia Parkinson’s disease dementia 

caprylidene donepezil galantamine memantine rivastigmine

haloperidol (adjunct) lorazepam (adjunct) 

donepezil galantamine memantine rivastigmine 

rivastigmine pimavanserin 

 

Note: For more information on Pimavanserin, see:

Acadia Pharmaceuticals. (2017). Transform the treatment of Parkinson’s disease psychosis with NUPLAZID. Retrieved from https://www.nuplazidhcp.com/?gclid=CIHS5auvwtMCFQkaaQodrU0FGQ

U.S. Food and Drug Administration. (n. d.). Highlights of prescribing information: Nuplazid. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/207318lbl.pdf

Hopkins, S. A., & Chan, D. (2016). Key emerging issues in frontotemporal dementia. Journal of Neurology, 263(2), 407–413. doi:10.1007/s00415-015-7880-7

Walker, Z., Possin, K. L., Boeve, B. F., & Aarsland, D. (2015). Lewy body dementias. The Lancet, 386(10004), 1683-1697.  

Required Media

Laureate Education (Producer). (2017a). A gentleman with a neurocognitive disorder [Multimedia file]. Baltimore, MD: Author.

 

Bolin, P. (2015, December 31). Neurocognitive disorders – CRASH! Medical review series [Video file]. Retrieved from https://www.youtube.com/watch?v=bQXOPITY9XM

 

Note: The approximate length of this media piece is 57 minutes.

Optional Resources

Kota, L. N., Bharath, S., Purushottam, M., Moily, N. S., Sivakumar, P. T., Varghese, M., . . . Jain, S. (2015). Reduced telomere length in neurodegenerative disorders may suggest shared biology. The Journal of Neuropsychiatry and Clinical Neurosciences, 27(2), e92–e96. doi:10.1176/appi.neuropsych.13100240

Lepkowsky, C. M. (2016). Neurocognitive disorder with Lewy bodies: Evidence-based diagnosis and treatment. Practice Innovations, 1(4), 234–242. doi:10.1037/pri0000031

Oltra-Cucarella, J., Pérez-Elvira, R., Espert, R., & Sohn McCormick, A. (2016). Are cognitive interventions effective in Alzheimer’s disease? A controlled meta-analysis of the effects of bias. Neuropsychology, 30(5), 631–652. doi:10.1037/neu0000283

 

. WITH nursingassignment.org AND GET AN AMAZING DISCOUNT!

Discussion: Treatment of Neurocognitive Disorders:Mild Cognitive Impairment was first posted on April 12, 2020 at 9:56 pm.
©2019 "nursingassignment.org". Use of this feed is for personal non-commercial use only. If you are not reading this article in your feed reader, then the site is guilty of copyright infringement. Please contact me at ukbestwriting@gmail.com

 

“Is this question part of your assignment? We will write the assignment for you. click order now and get up to 40% Discount”

Discussion: Treatment of Neurocognitive Disorders:Mild Cognitive Impairment was first posted on April 19, 2020 at 11:41 am.
©2019 "Nursing Assignment". Use of this feed is for personal non-commercial use only. If you are not reading this article in your feed reader, then the site is guilty of copyright infringement. Please contact me at support@nursingassignment.org

/by